Search

Your search keyword '"Casas R."' showing total 19 results
Start Over Author "Casas R." Publisher elsevier espana
19 results on '"Casas R."'

8. A prospective and multicenter safety-monitoring study of a short up-dosing schedule of immunotherapy with a mass-units-standardized extract of mites

Author

Gamboa, P., González, G., Jauregui, I., Jorró, G., Molero, I., Eseverri, J.L., González, R., Luna, I., Marcos, C., Miró, J., Pulido, Z., Gracia, T., Iriarte, P., Carreño, A., Navarro, J.A., Rocafort, S., García-Robaina, J.C., Souto, I., Casas, R., Lleonart, R., Nevot, S., Asensio, O., Bosque, M., Blasco, A., and de la Torre, F.

Published
2004
Full Text
View/download PDF

15. [Sublingual schwannoma].

Author

Guedes de Las Casas R, Duménigo Arias O, and Guerrero Osorio Y

Subjects
Adolescent, Humans, Male, Mouth Floor, Mouth Neoplasms pathology, Neurilemmoma pathology
Published
2013
Full Text
View/download PDF

16. [Chronic C hepatitis genotype 4].

Author

González-Casas R, Trapero-Marugán M, and Moreno-Otero R

Subjects
Genotype, Hepatitis C, Chronic drug therapy, Humans, Hepacivirus genetics, Hepatitis C, Chronic virology
Abstract

The hepatitis C virus (HCV) is one of the most important causal agents of liver disease. Genotype 4 is responsible for 20% of chronic hepatitis and in several countries of the Mediterranean area it has been reported that the prevalence is increasing. The HCV infection develops to chronicity in more than 90%, 20% may have cirrhosis and 5-10% develop hepatocellular carcinoma. There has been speculation about a possible association of genotype 4 with the development of hepatocellular carcinoma, but it seems related to other concomitant causes of liver disease. Treatment is based on the use of pegylated interferon α-2a (180 mg/week) or pegylated-interferon α-2b (1.5mg/kg/wk) plus ribavirin (1000-1200 mg/day) for one year. With this regimen, there have been reported sustained virological response (SVR) rates around 65%. There are differences in the SVR rates according to the degree of fibrosis, associated concurrent infections and the presence of specific serologic markers. Nitazoxanide has been used in combination with the classic combination therapy, achieving an improvement in the results., (Copyright © 2010 Elsevier España, S.L. All rights reserved.)

Published
2011
Full Text
View/download PDF

17. [Hepatic disease in hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber disease)].

Author

González-Casas R, Trapero-Marugán M, and Moreno-Otero R

Subjects
Antibiotic Prophylaxis, Cholangitis, Sclerosing etiology, Diagnostic Imaging methods, Embolization, Therapeutic, Heart Failure diet therapy, Heart Failure drug therapy, Heart Failure etiology, Humans, Hypertension, Portal therapy, Hypertension, Pulmonary etiology, Liver Cirrhosis surgery, Liver Transplantation, Sepsis etiology, Telangiectasia, Hereditary Hemorrhagic diagnosis, Telangiectasia, Hereditary Hemorrhagic epidemiology, Telangiectasia, Hereditary Hemorrhagic genetics, Telangiectasia, Hereditary Hemorrhagic therapy, Cholestasis etiology, Hypertension, Portal etiology, Liver blood supply, Liver Cirrhosis etiology, Telangiectasia, Hereditary Hemorrhagic complications
Published
2007
Full Text
View/download PDF

19. [Localized scleroderma (morphea) and septic arthritis. Clinical manifestations of Lyme borreliosis seen in El Ferrol].

Author

Maestre JR, Almagro M, Martínez P, de Casas R, Quesada R, and Egido J

Subjects
Adult, Antibodies, Bacterial blood, Borrelia burgdorferi Group immunology, Female, Fluorescent Antibody Technique, Humans, Incidence, Knee, Lyme Disease diagnosis, Lyme Disease epidemiology, Male, Middle Aged, Prevalence, Scleroderma, Localized diagnosis, Spain epidemiology, Lyme Disease complications, Scleroderma, Localized etiology
Abstract

Two cases of Lyme's disease seen at El Ferrol (Spain) were described. One of them developed a recurrent knee arthritis and the other had a localized sclerodermia (morphea) syndrome. Diagnosis was established by means of clinical picture and serologic tests (enzyme-linked analysis and/or indirect immunofluorescence tests). Joint involvement has often been described in patients diagnosed of having Lyme's disease in Spain, however, the relationship between morphea and borreliosis is still a matter of controversy. We believe that patients with localized sclerodermia and high significant titers of specific antibodies against B. burgdorferi should be treated with antimicrobial agents.

Published
1991

Catalog

Books, media, physical & digital resources
See catalog results